Informatie: Dit is niet de actueelste versie van het datamodel. Een versieoverzicht vindt u links onder Versies. De actueelste versie vindt u hier.
Informatie:
Fout:
ID
34346
Beschrijving
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516
Link
https://clinicaltrials.gov/show/NCT01933516
Trefwoorden
Versies (3)
- 16-01-19 16-01-19 -
- 26-04-20 26-04-20 -
- 01-05-20 01-05-20 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
16 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516
Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516
- StudyEvent: Eligibility
Similar models
Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
boolean
ID.2
Item
patient with at least one measurable lesion.
boolean
ID.3
Item
patient with ecog performance status 0 or 1.
boolean
ID.4
Item
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
boolean
ID.5
Item
patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
boolean
ID.6
Item
patient who has mab therapy other than rituximab as prior line of therapy.
boolean
ID.7
Item
patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
boolean
ID.8
Item
patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean